BAM
SRNE

Belpointe Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Belpointe Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,873
Closed -$15.8K – 3917
2022
Q4 		$15.8K Buy
+17,873
New +$23.7K ﹤0.01% 2346
2021
Q4 		– Sell
-15,923
Closed -$121K – 1271
2021
Q3 		$121K Sell
15,923
-400
-2% -$3.39K 0.01% 1075
2021
Q2 		$158K Buy
16,323
+2,300
+16% +$18.3K 0.01% 931
2021
Q1 		$116K Buy
+14,023
New +$148K 0.01% 945

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Belpointe Asset Management's SRNE Position: Q1 2023 in Review

Belpointe Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 17,873 shares — an estimated $15.8K sold.

Belpointe Asset Management first reported a position in SRNE in Q1 2021 and held it in 4 quarters. The position peaked at $158K in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Belpointe Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 17,873 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $15.8K.
  • Belpointe Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and held it in 4 quarters.
  • Belpointe Asset Management's Sorrento Therapeutics, Inc. position peaked at $158K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.